Neoadjuvant Hepatic Arterial Infusion Chemotherapy with FOLFOX Plus Tislelizumab for Resectable Hepatocellular Carcinoma Beyond the Milan Criteria: Efficacy, Safety and Biomarker Exploration
Quanwei Dai, Huiting Deng, Jun Wang, Jingxiang Shi, Jianmin Ding, Yanying Gao, Wei Sun, Yunzhi Shen, Ximo Wang, Cheng Lou · 2026
Read Neoadjuvant Hepatic Arterial Infusion Chemotherapy with FOLFOX Plus Tislelizumab for Resectable Hepatocellular Carcinoma Beyond the Milan Criteria: Efficacy, Safety and Biomarker Exploration by Quanwei Dai, Huiting Deng, Jun Wang, Jingxiang Shi, Jianmin Ding, Yanying Gao, Wei Sun, Yunzhi Shen, Ximo Wang, Cheng Lou (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13477671.txt.
Description
PurposeThis study aimed to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin (FOLFOX-HAIC) combined with tislelizumab as a neoadjuvant regimen in patients with resectable hepatocellular carcinoma (HCC) beyond the Milan criteria, and to explore predictive biomarkers of treatment response.Results26 patients completed neoadjuvant therapy, with a median tumor size of 6.35cm.
Catalog record
| CREATOR | Quanwei Dai, Huiting Deng, Jun Wang, Jingxiang Shi, Jianmin Ding, Yanying Gao, Wei Sun, Yunzhi Shen, Ximo Wang, Cheng Lou |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |